UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

The New England journal of medicine, 2020-04, Vol.382 (16), p.1520-1530

2020

Volltextzugriff (PDF)

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

The New England journal of medicine, 2020-04, Vol.382 (16), p.1507-1519

2020

Volltextzugriff (PDF)

Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study

Circulation (New York, N.Y.), 2020-06, Vol.141 (22), p.1829-1831

2020

Volltextzugriff (PDF)

Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies

Mayo Clinic proceedings, 2020-01, Vol.95 (1), p.77-89

2020

Volltextzugriff (PDF)

Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial

Diabetes care, 2019-01, Vol.42 (1), p.173-176

2019

Volltextzugriff (PDF)

Persistent changes in lipoprotein lipids after a single infusion of ascending doses of MDCO-216 (apoA-IMilano/POPC) in healthy volunteers and stable coronary artery disease patients

Atherosclerosis, 2016-12, Vol.255, p.17-24

2016

Volltextzugriff (PDF)

High-Density Lipoprotein Subfractions and Cholesterol Efflux Capacities After Infusion of MDCO-216 (Apolipoprotein A-IMilano/Palmitoyl-Oleoyl-Phosphatidylcholine) in Healthy Volunteers and Stable Coronary Artery Disease Patients

Arteriosclerosis, thrombosis, and vascular biology, 2016-04, Vol.36 (4), p.736

2016

Volltextzugriff (PDF)

The drug resistance-related protein LRP is the human major vault protein

Nature medicine, 1995-06, Vol.1 (6), p.578-582

1995

Volltextzugriff (PDF)

Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys

Journal of lipid research, 2013-09, Vol.54 (9), p.2341-2353

2013

Volltextzugriff (PDF)

Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis

Journal of the American College of Cardiology, 2021-03, Vol.77 (9), p.1182-1193

2021

Volltextzugriff (PDF)

Evaluation of the distribution and excretion of [14C]-inclisiran following single subcutaneous administration in cynomolgus monkeys

Toxicology and applied pharmacology, 2022-05, Vol.443, p.115978-115978, Article 115978

2022

Volltextzugriff (PDF)

Corrigendum to “Evaluation of the distribution and excretion of [14C]-inclisiran following single subcutaneous administration in cynomolgus monkeys” [Toxicology and Applied Pharmacology 443 (2022) 115978]

Toxicology and applied pharmacology, 2022-09, Vol.451, p.116144-116144, Article 116144

2022

Volltextzugriff (PDF)

Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial

JAMA cardiology, 2019-11, Vol.4 (11), p.1067

2019

Volltextzugriff (PDF)

The N‐Acetylgalactosamine‐conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low‐density lipoprotein cholesterol reductions

Pharmacology research & perspectives, 2023-04, Vol.11 (2), p.e01080-n/a

2023

Volltextzugriff (PDF)

siRNA to PCSK9 in patients with high cardiovascular risk and elevated LDL-C: the ORION 1 trial

Atherosclerosis, 2017-08, Vol.263, p.e9-e10

2017

Volltextzugriff (PDF)

Incubation of MDCO-216 (ApoA-IMilano/POPC) with Human Serum Potentiates ABCA1-Mediated Cholesterol Efflux Capacity, Generates New Prebeta-1 HDL, and Causes an Increase in HDL Size

Journal of Lipids, 2014-01, Vol.2014 (2014), p.923903-8

2014

Volltextzugriff (PDF)

CD63 antigen. A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells

The Journal of biological chemistry, 1991-02, Vol.266 (5), p.3239-3245

1991

Volltextzugriff (PDF)

Characterization of the gene encoding the polymorphic immunodominant molecule, a neutralizing antigen of Theileria parva

The Journal of immunology (1950), 1995-08, Vol.155 (3), p.1370

1995

Volltextzugriff (PDF)

Invited letter concerning: Transplantation tolerance and transplantation: Reply to the Editor

The Journal of thoracic and cardiovascular surgery, 1993-01, Vol.105 (1), p.185-185

1993

Volltextzugriff (PDF)

Endomyocardial biopsies after heart transplantation. The presence of markers indicative of activation

Transplantation, 1993-01, Vol.55 (1), p.103

1993

Volltextzugriff (PDF)

Innervation of the endomyocardium in the first period after heart transplantation

Transplantation, 1993-07, Vol.56 (1), p.85

1993

Volltextzugriff (PDF)

Breaking of transplantation tolerance after reduction of immunosuppression

The Journal of thoracic and cardiovascular surgery, 1993-01, Vol.105 (1), p.183-184

1993

Volltextzugriff (PDF)

Cytoimmunologic monitoring for rejection and infection after lung transplantation

The Journal of thoracic and cardiovascular surgery, 1993-01, Vol.105 (1), p.178-180

1993

Volltextzugriff (PDF)

Lymphocyte status in endomyocardial biopsies and blood after heart transplantation

The Journal of pathology, 1989-11, Vol.159 (3), p.197-203

1989

Volltextzugriff (PDF)

Endomyocardial biopsies after heart transplantation. The presence of immunoglobulin/immune complex deposits

Transplantation, 1989-09, Vol.48 (3), p.435

1989

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(24)
Science & Technology
(24)
Humans
(15)
Female
(8)
Male
(8)
Cardiovascular System & Cardiology
(7)
Animals
(6)
Biological And Medical Sciences
(6)
Cardiac & Cardiovascular Systems
(6)
Cardiovascular Disease
(6)
Cholesterol
(6)
Middle Aged
(6)
Time Factors
(6)
Cholesterol, Ldl - Blood
(5)
Dose-Response Relationship, Drug
(5)
Immunology
(5)
Surgery
(5)
Biochemistry & Molecular Biology
(4)
Cardiovascular Diseases
(4)
Coronary Artery Disease - Drug Therapy
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study

Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies

Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial

Persistent changes in lipoprotein lipids after a single infusion of ascending doses of MDCO-216 (apoA-IMilano/POPC) in healthy volunteers and stable coronary artery disease patients

High-Density Lipoprotein Subfractions and Cholesterol Efflux Capacities After Infusion of MDCO-216 (Apolipoprotein A-IMilano/Palmitoyl-Oleoyl-Phosphatidylcholine) in Healthy Volunteers and Stable Coronary Artery Disease Patients

The drug resistance-related protein LRP is the human major vault protein

Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys

Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis

Evaluation of the distribution and excretion of [14C]-inclisiran following single subcutaneous administration in cynomolgus monkeys

Corrigendum to “Evaluation of the distribution and excretion of [14C]-inclisiran following single subcutaneous administration in cynomolgus monkeys” [Toxicology and Applied Pharmacology 443 (2022) 115978]

Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial

The N‐Acetylgalactosamine‐conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low‐density lipoprotein cholesterol reductions

siRNA to PCSK9 in patients with high cardiovascular risk and elevated LDL-C: the ORION 1 trial

Incubation of MDCO-216 (ApoA-IMilano/POPC) with Human Serum Potentiates ABCA1-Mediated Cholesterol Efflux Capacity, Generates New Prebeta-1 HDL, and Causes an Increase in HDL Size

CD63 antigen. A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells

Characterization of the gene encoding the polymorphic immunodominant molecule, a neutralizing antigen of Theileria parva

Invited letter concerning: Transplantation tolerance and transplantation: Reply to the Editor

Endomyocardial biopsies after heart transplantation. The presence of markers indicative of activation

Innervation of the endomyocardium in the first period after heart transplantation

Breaking of transplantation tolerance after reduction of immunosuppression

Cytoimmunologic monitoring for rejection and infection after lung transplantation

Lymphocyte status in endomyocardial biopsies and blood after heart transplantation

Endomyocardial biopsies after heart transplantation. The presence of immunoglobulin/immune complex deposits

Suchergebnisse filtern